Advertisement

American Journal of Drug Delivery

, Volume 1, Issue 3, pp 215–221 | Cite as

Managing difficulties with adherence to injectable medications due to blood, injection, and injury phobia and self-injection anxiety

  • Darcy Cox
  • David C. MohrEmail author
Technology in Practice

Abstract

Injection phobia has long been known to interfere with the successful delivery of medical and dental care. Increasingly, as new biological medications administered through regular injection are developed, the inability to self-inject due to anxiety is reducing initiation and adherence to treatment. The prevalence of injection phobia ranges from 7–22% of the general population, while the inability to self-inject may also be increasingly prevalent.

Specific phobia — blood, injection, and injury (BII) — is a diagnosis that is characterized by phobic reactions to exposure to injections, injury, or blood, leading to avoidance of such situations, or tolerating these situations only under extreme emotional duress. While the literature on health outcomes related to injection phobia is somewhat limited, injection phobia has been shown to contribute to poor adherence to treatment regimens, or to discontinuance of treatment altogether in diabetes mellitus and multiple sclerosis. Hypotheses about possible psychological and genetic mechanisms have been developed, as well as high psychiatric comorbidities that may contribute to injection anxiety and phobia, or complicate medical treatment. A number of psychological factors, including poor self-efficacy about self-injecting, beliefs about the benefits and risks associated with injecting, and feelings of disgust may contribute to injection phobia. Increased occurrence of vasovagal responses during or following injection may also increase the risk of injection phobia. Because injection phobia can prevent or interfere with the delivery of needed medications, it is believed that injection phobia and self-injection anxiety can have health consequences, however, research in this area is lacking. Cognitive behavioral therapies, including both exposure and cognitive restructuring, have been shown to be an effective treatment.

Keywords

Multiple Sclerosis Migraine Specific Phobia Cognitive Restructuring Blood Glucose Testing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Dr Cox is supported in part by National Multiple Sclerosis Society grant FG-1376-A-1. Dr Mohr is supported by R01 MH59708-01 from the National Institute of Mental Health, and R01 HD043323-01 from the National Institute of Child Health and Human Development. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001; 23: 125–32PubMedCrossRefGoogle Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  3. 3.
    Glasgow RE, McCaul KD, Schafer LC. Barriers to regimen adherence among persons with insulin-dependent diabetes. J Behav Med 1986; 9: 65–77PubMedCrossRefGoogle Scholar
  4. 4.
    Johnson SB. Compliance and control in insulin-dependent diabetes: does behavior really make a difference? In: Scheiderman N, McCabe P, Baum A, editors. Perspectives in behavioral medicine: stress and disease processes. Hillsdale (NJ): Erlbaum, 1992Google Scholar
  5. 5.
    Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000; 75: 782–9PubMedCrossRefGoogle Scholar
  6. 6.
    Hurst DS, Gordon BS, Fornadley JA, et al. Safety of home-based and office allergy immunotherapy: a multicenter prospective study. Otolaryngol Head Neck Surg 1999; 121: 553–61PubMedCrossRefGoogle Scholar
  7. 7.
    The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis (I): clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61CrossRefGoogle Scholar
  8. 8.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–94PubMedCrossRefGoogle Scholar
  9. 9.
    Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268–76PubMedCrossRefGoogle Scholar
  10. 10.
    Manecke R, Mulhall J. Medical treatment of erectile dysfunction. Ann Med 1999; 31(6): 388–98PubMedCrossRefGoogle Scholar
  11. 11.
    Gocial B, Keye WR, Fein SH, et al. Repronex SC ISG: subcutaneously administered Repronex in female patients undergoing in vitro fertilization is as effective and well tolerated as intramuscular menotropin treatment. Fertil Steril 2000; 74(1): 73–9PubMedCrossRefGoogle Scholar
  12. 12.
    Esposito S. Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages. Drugs 2000; 59(3): 19–28PubMedCrossRefGoogle Scholar
  13. 13.
    National Institute of Diabetes and Digestive and Kidney Disease. National diabetes statistics fact sheet: general information and national statistics on diabetes in the United States, 2000. Bethesda (MD): US Department of Health and Human Services, National Institutes of Health; 2002 May. Publication no. 02-3892Google Scholar
  14. 14.
    Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. JAMA 2001; 41: 646–57Google Scholar
  15. 15.
    Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999; 46: 239–46PubMedCrossRefGoogle Scholar
  16. 16.
    Mollema E, Snoek F, Ader HJ, et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res 2001; 51: 665–72PubMedCrossRefGoogle Scholar
  17. 17.
    Berlin I, Bisserbe J-C, Eiber R, et al. Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type 1 diabetic adults. Diabetes Care 1997; 20(2): 176–8PubMedCrossRefGoogle Scholar
  18. 18.
    Bienvenu OJ, Eaton WW. The epidemiology of blood-injection-injury phobia. Psychol Med 1998; 28: 1129–36PubMedCrossRefGoogle Scholar
  19. 19.
    Poulton R, Thomson W, Brown R, et al. Dental fear with and without blood-injection fear: implications for dental health and clinical practice. Behav Res Ther 1998; 36: 591–7PubMedCrossRefGoogle Scholar
  20. 20.
    Agras S, Sylvester D, Oliveau D. The epidemiology of common fears and phobia. Compr Psychiatry 1969; 10: 151–6PubMedCrossRefGoogle Scholar
  21. 21.
    Cartwright PS, McLaughlin FJ, Martinez AM, et al. Teenagers’ perceptions of barriers to prenatal care. South Med J 1993; 86: 737–41PubMedCrossRefGoogle Scholar
  22. 22.
    Costello CG. Fears and phobias in women: a community study. J Abnorm Psychol 1982; 4: 280–6CrossRefGoogle Scholar
  23. 23.
    Antony MM, Brown TA, Barlow DH. Heterogeneity among specific phobia types in DSM-IV. Behav Res Ther 1997; 35(12): 1089–100PubMedGoogle Scholar
  24. 24.
    Muris P, Schmidt H, Merckelbach H. The structure of specific phobia symptoms among children and adolescents. Behav Res Ther 1999; 37: 863–969PubMedCrossRefGoogle Scholar
  25. 25.
    Lipsitz JD, Barlow DH, Mannuzza S, et al. Clinical features of four DSM-IV specific phobia subtypes. J Nerv Ment Dis 2002; 190(7): 471–8PubMedCrossRefGoogle Scholar
  26. 26.
    Ost L-G. Blood and injection phobia: background and cognitive, physiological, and behavioral variables. J Abnorm Psychol 1992; 101(1): 68–74PubMedCrossRefGoogle Scholar
  27. 27.
    De Jongh A, Bongaarts G, Vermeule I, et al. Blood-injury-injection phobia and dental phobia. Behav Res Ther 1998; 36: 971–82PubMedCrossRefGoogle Scholar
  28. 28.
    Kaakko T, Coldwell SE, Getz T, et al. Psychiatric diagnoses among self-referred dental injection phobics. J Anxiety Disord 2000; 14(3): 299–312PubMedCrossRefGoogle Scholar
  29. 29.
    Starcevic V, Bogojevic G. Comorbidity of panic disorder with agoraphobia and specific phobia: relationship with subtypes of specific phobia. Compr Psychiatry 1997; 38(6): 315–20PubMedCrossRefGoogle Scholar
  30. 30.
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–7PubMedCrossRefGoogle Scholar
  31. 31.
    Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996; 2: 222–6PubMedGoogle Scholar
  32. 32.
    Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54: 531–3PubMedCrossRefGoogle Scholar
  33. 33.
    Kleinknecht RA, Thorndike RM, Walls MM. Factorial dimensions and correlates of blood, injury, injection and related medical fears: cross validation of the medical fear survey. Behav Res Ther 1996; 34(4): 323–31PubMedCrossRefGoogle Scholar
  34. 34.
    Hamilton JG. Needle phobia: a neglected diagnosis. J Fam Pract 1995; 41: 169–75PubMedGoogle Scholar
  35. 35.
    Hellstrom K, Ost L-G. Prediction of outcome in the treatment of specific phobia: a cross-validation study. Behav Res Ther 1996; 34(5/6): 403–11PubMedCrossRefGoogle Scholar
  36. 36.
    Page A, Martin N. Testing a genetic structure of blood-injury-injection fears. Am J Med Genet 1998; 81: 377–84PubMedCrossRefGoogle Scholar
  37. 37.
    Cox D, Mohr DC, Epstein L. Treating self-injection phobia in patients prescribed injectable medications: case example illustrating a six-session treatment model. Cognit Behav Pract. In pressGoogle Scholar
  38. 38.
    Sawchuk CN, Lohr JM, Lee TC, et al. Exposure to disgust-evoking imagery and information processing biases in blood-injection-injury phobia. Behav Res Ther 1999; 37: 249–57PubMedCrossRefGoogle Scholar
  39. 39.
    Koch MD, O’Neill H, Sawchuk CN, et al. Domain-specific and generalized disgust sensitivity in blood-injection-injury phobia: the application of behavioral approach/avoidance tasks. Anxiety Disord 2002; 16: 511–27CrossRefGoogle Scholar
  40. 40.
    Ferguson JM, Taylor CB, Wermuth B. A rapid behavioral treatment for needle phobies. J Nerv Ment Dis 1978; 166: 294–8PubMedCrossRefGoogle Scholar
  41. 41.
    Trijsburg RW, Jelicic M, van den Broek WW, et al. Exposure and participant modelling in a case of injection phobia. Psychother Psychosom 1996; 65: 57–61PubMedCrossRefGoogle Scholar
  42. 42.
    Thompson A. Cognitive-behavioural treatment of blood-injury-injection phobia: a case study. Behav Change 1999; 16(3): 182–90CrossRefGoogle Scholar
  43. 43.
    Jacobsen JB. Treating a man with needle phobia who requires daily injections of medication. Hosp Community Psychiatry 1991; 42: 877–8PubMedGoogle Scholar
  44. 44.
    Ellinwood EH, Hamilton JG. Case report of a needle phobia. J Fam Pract 1991; 32: 420–2PubMedGoogle Scholar
  45. 45.
    Horne DJ, McCormack HM, Collins JP, et al. Psychological treatment of phobic anxiety associated with adjuvant chemotherapy. Med J Aust 1986; 145: 346–8PubMedGoogle Scholar
  46. 46.
    Ost L-G, Hellstroem K, Kaver A. One versus five sessions of exposure in the treatment of injection phobia. Behav Ther 1992; 23: 263–82CrossRefGoogle Scholar
  47. 47.
    Mohr DC, Cox D, Epstein L, et al. Teaching patients to self-inject: treating injection anxiety and phobia in patients prescribed injectable medications. J Behav Ther Exp Psychiatry 2002; 33: 39–47PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Departments of Psychiatry and NeurologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations